Dr. Chandler Park, a medical oncologist of Genitourinary Medical Oncology, on the Norton Healthcare Institute, in Louisville, Kentucky, sat down for an interview with CURE® to debate the most important takeaway from the 2025 Annual ASCO Genitourinary (GU) Cancers Symposium by way of prostate most cancers therapy.
The TALAPRO-2 research, a big section 3 trial introduced on the assembly, evaluated the mixture of Xtandi (enzalutamide) and Talzenna (talazoparib) in metastatic castration-resistant prostate most cancers, he defined. The investigative agent demonstrated a 20% discount in most cancers development no matter BRCA1/BRCA2 mutation standing, with potential future FDA approval, in response to the knowledgeable.
Learn extra from our interview with Park on extra takeaways from the assembly encompassing bladder and kidney most cancers, in addition to our dialog with him on the significance of precision drugs in oncology.
Transcript:
[An important] research that’s within the prostate most cancers area is the TALAPRO-2 research. The [trial looked at] sufferers with prostate most cancers after they’re recognized. There are two forms of prostate most cancers: one is named metastatic-hormone delicate prostate most cancers, and that signifies that these sufferers are nonetheless delicate to testosterone, so we give them testosterone blockers — sort of like estrogen blockers for sufferers with breast most cancers; however the extra aggressive kind is named castrate-resistant prostate most cancers. This [diagnosis] could be very powerful and we need to discover new therapies for this.
In TALAPRO-2, sufferers obtained randomized to Xtandi, which is taken into account an excellent customary of care therapy for metastatic castration-resistant prostate most cancers, and the opposite arm acquired Xtandi plus Talzenna, which is taken into account a PARP inhibitor. Now, PARP inhibitors are one thing that we would all hear about after we deal with for sufferers in ovarian most cancers, breast most cancers and pancreatic most cancers, and the bottom line is they want these genetic markers referred to as BRCA1 and BRCA2. It was very related within the prostate most cancers world, the place sufferers needed to have both the BRCA1 or BRCA2 mutations; these mutations might be both within the germline or the somatic.
Germline is each time a buccal swab or blood test [is done] to see if [patients] inherited BRCA1/BRCA2 genes. Now, what’s somatic mutation? Think about if I’ve a black mark on my hand, and that mark is melanoma. In the event that they take a biopsy of this black a part of my hand, and so they take a biopsy of my regular hand, the DNA of that most cancers is totally totally different from the pores and skin, and that’s referred to as somatic mutation. If there is a BRCA1/BRCA2 mutation contained in the most cancers, then you might qualify for a PARP inhibitor. Now, with all that stated, that’s thought-about a choose affected person inhabitants; we should see if the sufferers qualify for a PARP inhibitor on this research.
What makes this research, as we thought-about it, a spotlight at ASCO GU, is that they did not take a look at that by way of randomizing sufferers to the research, they took all comers. It was near 800 sufferers, a big section 3 trial, wherein sufferers obtained randomized to Xtandi versus Xtandi plus Talzenna, and there was a 20% lower by way of the most cancers.
Lots is predicated upon the molecular subgroups, however it’s encouraging that if a affected person reveals up with metastatic castration-resistant prostate most cancers [we could refer to this]. Though I like to recommend everyone [complete testing], not everyone practices within the huge metropolis. Some individuals apply in rural America, and they may not have entry [to germline and somatic testing]. So if they do not have entry, and these oncologists see sufferers… [they should focus on family history of cancer], as there is perhaps some sort of genetic concern for most cancers. In these conditions, I might contemplate this primarily based upon the ASCO GU research. Now, it isn’t FDA authorized but, however I anticipate will probably be, so we’ll cross our fingers.
These are the three impactful research that I see for affected person care [following the ASCO GU Symposium].
Transcript has been edited for readability and conciseness.
For extra information on most cancers updates, analysis and schooling, don’t neglect to subscribe to CURE®’s newsletters right here.
